Regeneron (REGN) Halted Ahead of FDA Panel Review of Praluent
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/12/2026
- Wall Street posts weekly gains with earnings, inflation data on tap
- Oil prices settle higher as more production shut ahead of hurricane
- Apple cuts iPhone 18 Pro orders due to soft demand, Nikkei Asia reports
- UBS flags level in gold prices where dip buyers will likely emerge
- Telecom stocks tumble on SpaceX spectrum acquisition news
Tweet
Share
E-mail
Get Alerts REGN Hot Sheet
Join SI Premium – FREE
(Updated - June 9, 2015 7:05 AM EDT)
Regeneron (NASDAQ: REGN) trading halted with news pending.
UPDATE - The halt comes ahead of the U.S. FDA's Endocrinologic and Metabolic Drugs Advisory Committee, which will review Regeneron and Sanofi's PCSK9 (proprotein convertase subtilisin/kexin type 9) antibody, Praluent.
BMO Capital recently commented on the matter here, and RBC Capital commented here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Partners Value Split Corp. prices $125M preferred share offering
- BMO Capital maintains Outperform rating on Assurant amid SpaceX news
- Regeneron Pharma (REGN) PT Raised to $810 at RBC Capital
Create E-mail Alert Related Categories
FDA, Trading HaltsRelated Entities
BMO Capital, RBC CapitalSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
